Nevertheless, further research involving larger patient cohorts is necessary to establish definitive cut-off values and validate the clinical utility of blood TGF-β levels as a supportive tool for decision-making in the management of intracranial aneurysms. The gene discussed is TGFB1; the disease is Dilatation of the cerebral artery.